Underwater inspection system for nuclear power facilities
    1.
    发明授权
    Underwater inspection system for nuclear power facilities 失效
    核电设施水下检验系统

    公开(公告)号:US5912934A

    公开(公告)日:1999-06-15

    申请号:US892625

    申请日:1997-07-14

    IPC分类号: G21C17/08 G21C19/02 G21C17/00

    摘要: A nuclear fuel identification system for use in nuclear power plants has an imaging system having a video camera and an array of illuminators surrounding the video camera and positioned to shine onto a nuclear fuel cell. The illuminators are sequentially activated to provide a series of images each having a different shadow pattern. These images are then digitized and stored until a complete set of the images are available. At that time, the images are superimposed and optimized for improved contrast. By viewing the distinct shadow patterns on the nuclear fuel cell, the identifying markings are readily visible. In addition to the shadow imaging system, a variety of laser devices are used to accomplish similar image generating functions. Such laser devices include a laser scanner, a distance laser device, an interferometer, a holographic interferometer, and a bi-refringent crystal prism.

    摘要翻译: 用于核电站的核燃料识别系统具有成像系统,该成像系统具有摄像机和围绕摄像机的照明器阵列并定位成照射到核燃料电池上。 依次启动照明器以提供一系列具有不同阴影图案的图像。 然后将这些图像数字化并存储,直到完整的图像集合可用。 那时,图像被叠加和优化,以提高对比度。 通过观察核燃料电池上的不同阴影图案,识别标记是容易可见的。 除了阴影成像系统之外,还使用各种激光装置来实现类似的图像生成功能。 这种激光装置包括激光扫描器,距离激光装置,干涉仪,全息干涉仪和双重反射晶体棱镜。

    Substituted heterocyclic compounds and methods of use
    3.
    发明授权
    Substituted heterocyclic compounds and methods of use 失效
    取代的杂环化合物及其使用方法

    公开(公告)号:US07442698B2

    公开(公告)日:2008-10-28

    申请号:US10891636

    申请日:2004-07-13

    摘要: The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula I: and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.

    摘要翻译: 本发明涉及具有通式I的嘧啶或吡啶氨基甲酸酯化合物及其药学上可接受的盐或衍生物。 还包括治疗各种疾病和病症的方法,包括炎症,T细胞活化和增殖的抑制,关节炎,器官移植,缺血或再灌注损伤,心肌梗塞,中风,多发性硬化,炎性肠病,克罗恩病,狼疮, 超敏反应,1型糖尿病,牛皮癣,皮炎,桥本甲状腺炎,干燥综合征,自身免疫性甲状腺功能亢进,艾迪生病,自身免疫性疾病,肾小球性肾炎,过敏性疾病,哮喘,干草病,湿疹,癌症,结肠癌,胸腺瘤,仅举几例 哺乳动物,所述方法包括给予治疗有效量的如上所述的式I化合物或其盐或衍生物形式。